Synermore CEO Dr. Eric Tsao was Invited to present at Bio Taiwan 2016

Synermore completed the new round of fund-raising with one hundred and ninety-nine million RMB capital increase

Synermore’s anti-asthma biosimilar drug SYN008 has been approved by Australia TGA for the clinical phase I trial

SYN023, Synermore’s human rabies immunoglobulin antibody drug submitted IND application to CFDA for the Clinical Phase I trial study

SYN023, Synermore’s human rabies immunoglobulin antibody drug received IND approval from FDA for the Clinical Phase I trial study

SYN023, Synermore’s human rabies immunoglobulin antibody drug submitted IND application to FDA for the Clinical Phase I trial study

Synermore Biologics Co. Ltd. Opening ceremony in Taibei

Synermore completed two hundred and sixty million Taiwan yuan ($8.25 million) cash capital increase

Synermore’s anti-asthma biosimilar drug SYN008 has been submitted to CFDA for the first phase of human clinical trials

SYN004, an anti-colorectal cancer antibody drug received IND approval from FDA for the Clinical Phase I Study